CD19 and lymphoma: Immunotherapy has become a rapidly developing area with recent successes in treating CD19+ hematological malignancies with CAR-T cells [13–15], in the investigation of check-point blockade for melanoma, [16] lymphoma [17] and other cancers [18], and in the use of monoclonal antibodies directed against various cancers [19, 20].